Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Inventory (2017 - 2025)

Neurocrine Biosciences' Inventory history spans 9 years, with the latest figure at $69.0 million for Q4 2025.

  • For Q4 2025, Inventory rose 20.21% year-over-year to $69.0 million; the TTM value through Dec 2025 reached $69.0 million, up 20.21%, while the annual FY2025 figure was $69.0 million, 20.21% up from the prior year.
  • Inventory reached $69.0 million in Q4 2025 per NBIX's latest filing, roughly flat from $69.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $69.3 million in Q3 2025 to a low of $25.5 million in Q3 2021.
  • Average Inventory over 5 years is $40.7 million, with a median of $36.0 million recorded in 2022.
  • Peak YoY movement for Inventory: dropped 22.16% in 2023, then soared 59.03% in 2024.
  • A 5-year view of Inventory shows it stood at $30.5 million in 2021, then increased by 15.08% to $35.1 million in 2022, then increased by 9.12% to $38.3 million in 2023, then soared by 49.87% to $57.4 million in 2024, then grew by 20.21% to $69.0 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Inventory are $69.0 million (Q4 2025), $69.3 million (Q3 2025), and $56.9 million (Q2 2025).